A recent metabolomic profiling demonstrated that glycolysis was excessive via PI3K/AKT/mTOR and RAS/MAPK Signaling in methotrexate-resistant PCNSL-derived cells, which is valuable to understanding targeted therapies with selective anticancer drugs in recurrent CNS lymphoma [42]. This evidence concerns the gene AKT1 and primary central nervous system lymphoma.